Richter will continue to grow R&D spending in 2021, given that CNS and in biosimilars projects are entering into the clinical phase • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
